Abstract: A device for treating vapors includes a fluid-tight container that has a vapor inlet, a vapor outlet and a through-flow connection which connects the vapor inlet to the vapor outlet in particular along a direction of flow, wherein the container can be at least partially filled with a cooling fluid.

Abstract: A cleaning insert for removable arrangement in a cooking space of a cooking appliance includes a receiving device for receiving a cleaning unit with a cleaning composition in a reversibly fixed manner, and a supporting body connected to the receiving device for positioning the receiving device relative to the cooking space.

Abstract: The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan is present in a solubilized form. The formulations have therapeutically and commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solution after reconstitution in water or an aqueous solvent. Levosimendan or (?)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.

Abstract: The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan ispresent in a solubilized form. The formulations have therapeuticallyand commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solutionafter reconstitution in wateror an aqueous solvent. Levosimendan or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.

Abstract: The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate, said penetrants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetermined area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier.

Abstract: The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate, said penerants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetermined area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier.

Abstract: A method of casting a directionally solidified (DS) or single crystal (SX) article with a casting furnace having a heating chamber (4), a cooling chamber (5), a separating baffle (3) between the both chambers includes a first step in which the shell mould (12) is filled with liquid metal (15), and the liquid metal (15) is directionally solidified by withdrawing the shell mould (12) from the heating to the cooling chamber (4, 5). An inert gas impinges from nozzles (8) arranged below the baffle (3) on the shell mould (12) and in steep transitions in outer surface area of the shell mould (12) the flow of the inert gas (9) is reduced or even stopped and when a protruding geometrical feature has passed the impingement area of the gas jets, the gas flow (9) is restored to a value adjusted to the geometry of the cast part presently passing the impingement area.

Abstract: Tripeptide boronic acids of (R,S,R) configuration, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, and their use to make base addition salts of such acids. The salts are formulated into anti-thrombotic pharmaceutical formulations.

Abstract: The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate, said penetrants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetermined area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier.

Abstract: Organoboronic acids, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, are made by hydrolysing their diethanolamine adducts under conditions which avoid substantial C—B bond breakage. The product acids are substantially free of degradation product derived from cleavage of the C—B bond thereof. The acids are used to make base addition salts thereof. The salts are formulated into anti-thrombotic pharmaceutical formulations.

Abstract: A method of casting a directionally solidified (DS) or single crystal (SX) article with a casting furnace having a heating chamber (4), a cooling chamber (5), a separating baffle (3) between the both chambers includes a first step in which the shell mould (12) is filled with liquid metal (15), and the liquid metal (15) is directionally solidified by withdrawing the shell mould (12) from the heating to the cooling chamber (4, 5). An inert gas impinges from nozzles (8) arranged below the baffle (3) on the shell mould (12) and in steep transitions in outer surface area of the shell mould (12) the flow of the inert gas (9) is reduced or even stopped and when a protruding geometrical feature has passed the impingement area of the gas jets, the gas flow (9) is restored to a value adjusted to the geometry of the cast part presently passing the impingement area.

Abstract: The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate, said penerants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetermined area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier.